BEAM240920P23000
- 0.40
- 0.000.00%
Beam Therapeutics Newsroom
Beam Therapeutics Analyst Ratings
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80
Analysts Are Bullish on Top Healthcare Stocks: Beam Therapeutics (BEAM), Taysha Gene Therapies (TSHA)
Beam Therapeutics: Hold Rating With Stable Financial Outlook Amid Clinical Pipeline Progress and Upcoming Data Releases
Beam Therapeutics Price Target Cut to $31.00/Share From $33.00 by Barclays
Beam Therapeutics Analyst Ratings
Analysts Conflicted on These Healthcare Names: Nyxoah (NYXH), MultiPlan (MPLN) and Beam Therapeutics (BEAM)
Barclays Keeps Their Hold Rating on Beam Therapeutics (BEAM)
Beam Therapeutics' Advancements Bolster Buy Rating: Momentum in Gene Editing Trials and Regulatory Progress
Beam Therapeutics Analyst Ratings
H.C. Wainwright Initiates Beam Therapeutics(BEAM.US) With Buy Rating, Announces Target Price $80
Analysts' Opinions Are Mixed on These Healthcare Stocks: Beam Therapeutics (BEAM), Cormedix (CRMD) and Applied Therapeutics (APLT)
Beam Therapeutics: A Hold Rating Amid Controlled R&D Spending and Upcoming Clinical Milestones
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Beam Therapeutics (BEAM) and Mirum Pharmaceuticals (MIRM)
Beam Therapeutics Analyst Ratings
Barclays Maintains Equal-Weight on Beam Therapeutics, Lowers Price Target to $33
Beam Therapeutics Analyst Ratings
Beam Therapeutics: A Buy Rating Amidst Gene Editing Industry Developments
Beam Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Beam Therapeutics (BEAM) and Glaukos (GKOS)